1-5 of 5
Ying-Ming Jou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath
Journal: Blood
Blood (2022) 140 (Supplement 1): 8089–8091.
https://doi.org/10.1182/blood-2022-158627
Published: 2022
Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw
Journal: Blood
Blood (2018) 132 (Supplement 1): 927.
https://doi.org/10.1182/blood-2018-99-111279
Published: 2018
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Clinical Trials & Observations
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo
Journal: Blood
Blood (2016) 127 (23): 2833–2840.
https://doi.org/10.1182/blood-2016-01-694604
Published: 2016
Includes: Supplemental data
Journal Articles

Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

Antonio Palumbo, MD, Massimo Offidani, MD, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, MD, Kamel Laribi, Alberto Bosi, MD, Roberto Marasca, MD, Jacob P. Laubach, MD, Ann Mohrbacher, MD, Angelo Michele Carella, MD, Anil K. Singhal, Mark Lynch, Ying-Ming Jou, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2015) 126 (23): 510.
https://doi.org/10.1182/blood.V126.23.510.510
Published: 2015